logo
Canada has its 1st case of West Nile this year. Here's what to know about the virus

Canada has its 1st case of West Nile this year. Here's what to know about the virus

CTV News3 days ago
TORONTO — Confirmation of the first human case of West Nile virus acquired in Canada this year arrived just in time for the August long weekend.
The Public Health Agency of Canada said Thursday that an adult in Toronto with no travel history has been infected with the mosquito-borne virus. There had previously been two people with West Nile virus in Canada, but they were infected while travelling outside the country.
Here's what you need to know about West Nile virus as you head outdoors this weekend.
What is West Nile virus?
The first human case of West Nile virus appeared in Canada in 2002.
The virus was originally identified in the West Nile region of Uganda, said Dr. Isaac Bogoch, an infectious diseases specialist at the University Health Network in Toronto, but was carried to many places around the world by migratory birds.
When mosquitoes bite infected birds, they in turn become infected and then can pass on the virus to humans and other animals when they bite them.
The type of mosquitoes that transmit West Nile virus usually bite around dusk and at night, Bogoch said.
Human infections usually occur in mid to late summer, petering out as the temperature cools down.
The Public Health Agency of Canada says humans don't spread the virus to other humans, except for very rare cases including blood transfusions, organ or tissue transplants, mother-to-child transmission during pregnancy or breastfeeding.
What are the symptoms?
'The vast majority of people who are bitten by a mosquito harbouring West Nile virus will have no symptoms whatsoever,' said Bogoch.
For the 20 to 30 per cent of people who get sick, most will have a few days of symptoms that resolve on their own.
Symptoms usually begin between two and 14 days after the mosquito bite. They can include fever, muscle aches, headaches, fatigue, nausea, vomiting, skin rash, swollen lymph glands and a stiff neck.
The concerning part of West Nile virus is that up to two per cent of people infected will get neuroinvasive disease, including encephalitis or meningitis, Bogoch said.
Encephalitis is inflammation of the brain and meningitis is inflammation of the area around the brain and spinal cord.
In 'very rare' cases, people can also develop paralysis, he said.
Although anyone can get these severe West Nile virus infections, they tend to happen more in older adults, Bogoch said.
How is West Nile virus treated?
There is no antiviral medication to treat West Nile virus. Most people won't need medical attention and can manage aches and pains with over-the-counter acetaminophen, rest and fluids.
For the rare cases of neuroinvasive diseases, hospitals provide supportive care, including fluids and electrolytes, and provide rehabilitation if needed.
Is there a vaccine for West Nile virus?
There is no vaccine for West Nile virus.
How can I prevent West Nile virus?
The best way to prevent West Nile virus is to avoid being bitten by a mosquito in the first place.
Using insect repellent is 'very effective,' Bogoch said.
Both Bogoch and the Public Health Agency of Canada recommend using bug sprays and lotions containing the chemicals DEET or Icaridine. Health Canada says those products should not be used on infants under six months old and parents can use mosquito nets over cribs or strollers when babies are outside instead.
Wearing long sleeves and long pants, socks and a hat can also protect against mosquito bites. People can also wear mosquito nets over their hats. Choose light-coloured clothing, because mosquitoes are attracted to dark colours.
Making sure all open windows have screens to keep mosquitoes and other bugs out is important.
Getting rid of any standing water around your home or cottage also helps because that's where mosquitoes lay eggs. Drain buckets, planters, old tires, pool covers, wading pools and other objects where water accumulates.
How common is it?
The number of reported cases annually varies greatly since PHAC started tracking domestic infections in 2003, ranging from a handful of cases per year to a peak of 2,401 cases in 2007.
In 2024, there were 166 reported cases, according to PHAC's preliminary data.
'For most Canadians, the risk of getting infected is low because relatively few mosquitoes in Canada are infected with West Nile virus,' said Mark Johnson, a spokesperson for PHAC, in an email Friday.
This report by The Canadian Press was first published Aug. 2, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Nicole Ireland, The Canadian Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer raises annual profit forecast
Pfizer raises annual profit forecast

CTV News

time7 minutes ago

  • CTV News

Pfizer raises annual profit forecast

The Pfizer logo is displayed at the company's headquarters in New York. (AP Photo/Mark Lennihan, File) U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday after reporting better-than-expected results for the second quarter, boosted by strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis. The drugmaker now expects to earn US$2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80 to $3.00 per share. Shares of the drugmaker rose 2.4 per cent in premarket hours. Pfizer said the new forecast includes an impact of 20 cents per share related to its recent licensing deal with China's 3SBio for experimental cancer treatment. Pfizer's results come at a time when the pharmaceutical industry is under pressure from U.S. President Donald Trump's administration to lower drug prices and is gearing up for 15 per cent tariffs on imports from the European Union. The drugmaker has said it had enough manufacturing capacity across its 10 sites in the United States to mitigate any impact from tariffs and is open to shifting some production to these existing facilities. Investors are also closely monitoring potential disruptions to Pfizer and other companies' vaccine portfolio from policy changes under U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., a known vaccine skeptic. Vaccines account for about 20 per cent of Pfizer's revenues. On an adjusted basis, Pfizer earned 78 cents per share in the second quarter, compared with analysts' expectations of 58 cents per share, according to LSEG data. (Reporting by Bhanvi Satija in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva)

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia
Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

National Post

time7 minutes ago

  • National Post

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Article content SMITHS FALLS, Ontario — Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company's medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Article content Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES' top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. Article content 'Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options,' said Andrew Bevan, SVP, Global Medical. 'With recent improvements to our global supply chain, we're positioned to deliver these strains with consistent quality and reliable access to patients in Australia.' Article content 'Global medical is one of Canopy Growth's largest commercial opportunities,' said Luc Mongeau, Chief Executive Officer. 'Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform.' Article content The introduction of 7ACRES complements Canopy Growth's existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth's focus on building a scalable medical platform across international markets. Article content About Canopy Growth Article content Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Article content Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Article content Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology. Article content At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. Article content Article content Article content Article content Contacts Article content

Satellos to Present at Canaccord Genuity's 45th Annual Growth Conference
Satellos to Present at Canaccord Genuity's 45th Annual Growth Conference

National Post

time38 minutes ago

  • National Post

Satellos to Present at Canaccord Genuity's 45th Annual Growth Conference

Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the Canaccord Genuity's 45th Annual Growth Conference, taking place Aug. 13–14, 2025, at the InterContinental Boston. Article content Satellos management will present on Wed., Aug. 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will participate in one-on-one meetings during the conference. Article content Article content Canaccord Genuity's 45th Annual Growth Conference Article content Format: Presentation and Article content webcast Article content Article content Date: Wed., Aug. 13 Article content Article content Time: 12:30 p.m. ET Article content Article content Location: InterContinental Boston Article content The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, starting with DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Investors: Article content Liz Williams, CFO, Article content ir@ Article content Article content Media: Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store